Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBIT Margin: 2017-2025

Historic EBIT Margin for Protagonist Therapeutics (PTGX) over the last 6 years, with Sep 2025 value amounting to -985.17%.

  • Protagonist Therapeutics' EBIT Margin fell 9847.00% to -985.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.34%, marking a year-over-year decrease of 3818.00%. This contributed to the annual value of 58.20% for FY2024, which is 21429.00% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' EBIT Margin stood at -985.17%, which was down 29.96% from -758.04% recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year EBIT Margin high stood at 192,189.47% for Q4 2022, and its period low was -4,604.78% during Q2 2022.
  • For the 3-year period, Protagonist Therapeutics' EBIT Margin averaged around -428.15%, with its median value being -413.11% (2025).
  • Its EBIT Margin has fluctuated over the past 5 years, first spiked by 19,261,904bps in 2022, then plummeted by 19,214,338bps in 2023.
  • Over the past 5 years, Protagonist Therapeutics' EBIT Margin (Quarterly) stood at -429.57% in 2021, then spiked by 19,261,904bps to 192,189.47% in 2022, then slumped by 19,214,338bps to 46.10% in 2023, then surged by 3,074bps to 76.84% in 2024, then crashed by 9,847bps to -985.17% in 2025.
  • Its last three reported values are -985.17% in Q3 2025, -758.04% for Q2 2025, and -68.18% during Q1 2025.